Navigation Links
Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
Date:3/26/2013

CHARLOTTESVILLE, Virginia und CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ --

DART Therapeutics Inc., ein innovatives Biotechnologie-Unternehmen neuester Art, das sich auf die Entwicklung von Therapien für die Duchenne-Muskeldystrophie (DMD) konzentriert, und Biovista, ein führender Anbieter für die systematische Neupositionierung von Medikamenten, gaben heute bekannt, dass sie eine Forschungskooperation eingegangen sind, um neuartige Kandidaten für die Neupositionierung von Medikamenten für DMD zu identifizieren und zu entwickeln, wobei die Biovista-Technologie "Clinical Outcome Search Space" (COSS) ™ genutzt werden soll. Gemäß der Vereinbarung wird Biovista neuartige Kandidaten für die Neupositionierung identifizieren und die Firma DART Therapeutics wird die Möglichkeit haben, eine bestimmte Anzahl für die weitere Entwicklung auszuwählen. Die Bedingungen der Vereinbarung umfassen eine Vorauszahlung und nachgeschaltete erfolgsabhängige Zahlungen.

"Die Neupositionierung von Medikamenten ist ein wichtiger Ansatz in unserer Gesamtstrategie zur möglichst effizienten Identifikation neuartiger Behandlungsmethoden für DMD", sagte Gene Williams , Chief Executive Officer von DART Therapeutics. "Biovista und die COSS-Technologie sind führend in der systematischen Neupositionierung und gewährleisten uns die breitestmögliche Abdeckung aller Möglichkeiten der Neupositionierung, die wirklich starke Auswirkungen auf Patienten und ihre Familien haben können, die auf eine Behandlung für DMD warten."

"Das Unternehmen DART Therapeutics steht für ein einzigartiges Modell, das den Entwicklungsarm einer großen Interessengruppe von Patienten darstellt. Die Führungsrolle des Unternehmens bei DMD ist eine ausgezeichnete Ergänzung zu unseren eigenen F
'/>"/>

SOURCE Biovista, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... Agricultural firm H.J. Baker & Bro., ... of Tiger-Sul. Since the purchase of Tiger Industries ... May 2005, H.J. Baker has leveraged the innovation of ... comprehensive portfolio of product offerings and solutions expertise. The ... the innovation of Tiger-Sul, transforming the company into a ...
(Date:5/20/2015)... DIEGO , May 20, 2015  Cypher ... announced a collaboration with Celgene Corporation to apply ... genomic biomarkers that associate with patient response to ... is intended to help accelerate patient access to ... efficiencies in clinical research and development and potentially ...
(Date:5/20/2015)... North Carolina , 20. Mai ... Unternehmen für klinische Logistik (Clinical Logistics ... das Geschäftsjahr 2014, das am 31. ... Das Unternehmen hat die Marktentwicklung übertroffen ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... DENVER , May 20, 2015 /PRNewswire/ ... today announced that it is an official ... Management Executives (CHIME) Cooperative Members Services Program. ... of compliant, managed cloud services and best ... of healthcare CIOs and service providers, enabling ...
Breaking Biology Technology:Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 3
... cell controlled by a synthetic genome. They now hope to use ... engineer bacteria specially designed to solve environmental or energy problems. ... , at the Science Express website, on Thursday, 20 ... society. The research team, led by Craig Venter of the ...
... , May 20 Dendreon Corporation (Nasdaq: DNDN ) today ... PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, ... Oncology (ASCO) in Chicago on Monday, June 7 at ... , , ...
... May 20 Today, world-renowned scientist Dr. ... at the J. Craig Venter Institute (JCVI) became the first ... news holds groundbreaking potential for solutions to a host of ... cleaning up pollution; creating new energy sources; producing clean water; ...
Cached Biology Technology:Scientists 'boot up' a bacterial cell with a synthetic genome 2Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 2Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 3Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 4Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 5Science Channel Announces the Debut of Exclusive Look Into Dr. J. Craig Venter's Creation of Synthetic Life 2Science Channel Announces the Debut of Exclusive Look Into Dr. J. Craig Venter's Creation of Synthetic Life 3
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/17/2015)... Canada , April 17, 2015 ... growing security concerns, and technological advancement to drive ... until 2020   According ... Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems ... is projected to register growth at CAGR of ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... the latest issue of the journal Emerging Infectious ... the hyperboreal tundra, in connection with the tundra ... These findings indicate that resistance to antibiotics ... prospect for future health care. The scientists ...
... N.Y., JAN. 9, 2008 Not enough American women ... day can help prevent serious birth defects, and only ... essential nutrient beginning before pregnancy, two recent surveys show. ... beginning before pregnancy is crucial because birth defects of ...
... PA (January 11, 2008): Nucleonics, Inc., a ... of novel RNA interference (RNAi)-based therapeutics, announced today ... a Phase 1 human safety study of its ... infection, NUC B1000. NUC B1000 ( ...
Cached Biology News:High degree of resistance to antibiotics in Arctic birds 2New folic acid seal helps women choose enriched grain foods to help prevent birth defects 2New folic acid seal helps women choose enriched grain foods to help prevent birth defects 3Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 2Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 3
... allow for the rapid isolation of DNA from ... slice in the spin filter, centrifuge for 3 ... recovered. There is no need to melt agarose ... can also be used for buffer exchange, primer ...
Request Info...
Guinea Pig Complement...
Collected from sexually matured, mixed breed, mixed sex guinea pigs....
Biology Products: